Daiichi Sankyo, Inc. And Eli Lilly and Company: Heart Patients In England And Wales Offered More Choice Of Therapies As National Institute for Clinical Excellence (NICE) Extends Recommendations For Prasugrel

GERRARDS CROSS, England--(BUSINESS WIRE)--Revised guidance from the National Institute for Health and Care Excellence (NICE), recommends once-daily, oral antiplatelet prasugrel (Efient®), in combination with aspirin, as a cost-effective option when compared to generic clopidogrel, for a wider group of acute coronary syndrome (ACS) patients having primary or delayed percutaneous coronary intervention (PCI).1

Help employers find you! Check out all the jobs and post your resume.